论文部分内容阅读
Objective: Combined blockade of T-cell checkpoints by NIVO and IPI demonstrated a high objective response rate (ORR), promising overall survival (OS) and a manageable safety profile in pts with advanced MEL in a phase Ⅰ study, based on which an appropriate dose was selected for registrational trials.